Aug. 21 at 5:46 PM
Xtant Medical Holdings (NYSE-American:
$XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, reported Second Quarter 2025 financial results, including total revenue of
$35.4 Million, up 18% Year-over-Year.
Xtant Medical is a B2i Digital Featured Company. View the comprehensive profile at https://b2idigital.com/xtant-medical-1.
Additional highlights reported in the company’s Q2 2025 earnings release were:
• Gross margin of 68.6% compared to 62.1% for the prior year quarter.
• Net income of
$3.6 million compared to a net loss of
$3.9 million in the prior year quarter.
• Adjusted EBITDA of
$6.9 million compared to Adjusted EBITDA loss of
$0.6 million in the prior year quarter.
• Cash and cash equivalents of
$6.9 million as of June 30, 2025.
Sean Browne, President and CEO of Xtant Medical, noted in the release, “We delivered strong financial and operating results during the second quarter, reflecting steps taken to enhance our focus on our core biologics business while also prudently managing expenses across the organization and driving operating leverage, consistent profitability, and cash flow. Notably, with the recent launch of our next-generation growth factor, OsteoFactor Pro™, we are now the only vertically integrated company to develop and manufacture solutions across all major orthobiologic categories. Our recently announced agreements to sell certain non-core spinal implant and OUS businesses to Companion Spine represent another step toward the realization of our strategic vision for the company. Once completed, this transaction will allow us to significantly strengthen our balance sheet and further support the ongoing development of our broad pipeline of advanced biologics. I believe our tireless commitment to innovation and quality uniquely positions Xtant to address the needs of surgeons and patients alike while simultaneously creating enduring value for our shareholders.”
See the full news release at: https://investor.xtantmedical.com/news-releases/news-release-details/xtant-medical-reports-second-quarter-2025-financial-results
A replay of the quarterly conference call featuring President & CEO Sean Browne and CFO Scott Neils is available on the Investor section of the Company’s website at www.xtantmedical.com.
The company is led by Chief Executive Officer Sean Browne, Chief Financial Officer Scott Neils, and Chief Operating Officer Mark Schallenberger, whose collective experience spans medical-device commercialization, corporate finance, and orthobiologic innovation.
For more information, visit https://www.xtantmedical.com. Investor inquiries: Kevin Gardner at LifeSci Advisors,
[email protected].
Disclosure: The management of B2i Digital owns shares of unrestricted XTNT stock purchased in the open market, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the purchase or sale of XTNT or any security, nor does it offer any investment opinion. Conduct your own research and consult professional advisers before making investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/
